Press Release: Omniab to Report Second Quarter 2026 Financial Results on August 6

Dow Jones07-16 20:05
EMERYVILLE, Calif.--(BUSINESS WIRE)--July 16, 2026--

OmniAb, Inc. $(OABI)$, a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Conference Call and Webcast 

 
What:       OmniAb conference call to discuss second quarter 2026 financial 
            results and business updates 
 
Date:       Thursday, August 6, 2026 
 
Time:       4:30 p.m. Eastern time (1:30 p.m. Pacific time) 
 
Phone:      U.S. (833) 461-5787 
            International (585) 542-9983 
            Conference ID is 545137839 
 
Webcast:    Live and replay webcast of the call with slides will be available 
            here.

About OmniAb$(R)$

OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence$(TM)$ , which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716057438/en/ 

 
    CONTACT:    OmniAb, Inc.

investors@OmniAb.com

X@OmniAbTech

Alliance Advisors IR

Vivian Cervantes

vcervantes@allianceadvisors.com

(973) 873-7724

(END) Dow Jones Newswires

July 16, 2026 08:05 ET

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment